**Example Test Table**

The tests and associated laboratories and CPT codes contained within this document serve only as examples to help users navigate claims and corresponding coverage criteria; as such, they are not comprehensive and are not a guarantee of coverage or non-coverage. Please see the Concert Genetics Platform for a comprehensive list of registered tests.

<table>
<thead>
<tr>
<th>Policy Statement Sections</th>
<th>Example Tests (Labs)</th>
<th>Common CPT Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Known Familial Variant Analysis for Eye Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Known Familial Variant Analysis for Eye Disorders</strong></td>
<td>Targeted Mutation Analysis for a Known Familial Variant</td>
<td>81403</td>
</tr>
<tr>
<td><strong>Macular Degeneration</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Macular Degeneration</strong></td>
<td>Macula Risk (Arctic Medical Laboratories)</td>
<td>81479, 81599</td>
</tr>
<tr>
<td></td>
<td>Vita Risk (Arctic Medical Laboratories)</td>
<td>0205U</td>
</tr>
<tr>
<td></td>
<td>Macular Degeneration NGS Panel (Fulgent Genetics)</td>
<td>81404, 81406, 81408, 81479</td>
</tr>
<tr>
<td><strong>RPE-Associated Retinal Dystrophy/Leber Congenital Amaurosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RPE65 Sequencing and/or Deletion/Duplication Analysis or Multigene Panel Analysis</strong></td>
<td>RPE65-Association Disorders via the RPE65 Gene (PreventionGenetics, part of Exact Sciences)</td>
<td>81406, 81479</td>
</tr>
<tr>
<td></td>
<td>Leber Congenital Amaurosis Panel (PreventionGenetics, part of Exact Sciences)</td>
<td>81404, 81406, 81408, 81479</td>
</tr>
<tr>
<td><strong>Glaucoma</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Glaucoma</strong></td>
<td>Glaucoma Panel (PreventionGenetics, part of Exact Sciences)</td>
<td>81404, 81406, 81407, 81408, 81479</td>
</tr>
<tr>
<td></td>
<td>Glaucoma Panel (Blueprint Genetics)</td>
<td></td>
</tr>
<tr>
<td><strong>Covered Eye Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other Covered Eye Disorders</strong></td>
<td>See below</td>
<td>81400-81408</td>
</tr>
</tbody>
</table>

**Policy Statement**

**KNOWN FAMILIAL VARIANT ANALYSIS FOR EYE DISORDERS**

I. Targeted mutation analysis for a known familial variant (81403) for an eye disorder may be considered **medically necessary** when:

A. The member has a **close relative** with a known pathogenic or likely pathogenic variant causing the condition.
II. Targeted mutation analysis for a known familial variant (81403) for an eye disorder is considered *investigational* for all other indications.

**MACULAR DEGENERATION**

III. Genetic testing for *macular degeneration* (81404, 81406, 81408, 81479, 81599, 0205U) is considered *investigational*.

**RPE65-ASSOCIATED RETINAL DYSTROPHY / LEBER CONGENITAL AMAUROSIS**

*RPE65 Sequencing and/or Deletion/Duplication Analysis or Multigene Panel Analysis*

IV. Genetic testing for *RPE65-associated retinal dystrophy/Leber congenital amaurosis* via *RPE65* sequencing and/or deletion/duplication analysis (81404, 81479) or a multigene panel (81404, 81406, 81408, 81479) that includes *RPE65* may be considered *medically necessary* when BOTH of the following criteria are met:

A. The member has a diagnosis of a retinal dystrophy or Leber Congenital Amaurosis
B. The member is being considered for treatment with voretigene neparvovec (Luxturna®).

V. Genetic testing for *RPE65-associated retinal dystrophy/Leber congenital amaurosis* via *RPE65* sequencing and/or deletion/duplication analysis (81404, 81406, 81408, 81479) or a multigene panel (81404, 81406, 81408, 81479) that includes *RPE65* is considered *investigational* for all other indications.

**GLAUCOMA**

VI. Genetic testing for glaucoma (81404, 81406, 81407, 81408, 81479) is considered *investigational*.

**OTHER COVERED EYE DISORDERS**

The following is a list of conditions that have a known genetic association. Due to their relative rareness, it may be appropriate to approve claims for these tests to establish or confirm a diagnosis.

VII. Genetic testing to establish or confirm one of the following eye disorders to guide management may be considered *medically necessary* when the member demonstrates clinical features* consistent with the disorder (the list is not meant to be comprehensive, see VIII below):

A. *Duane Syndrome*
B. *Familial Exudative Vitreoretinopathy*
C. *Retinitis Pigmentosa*
D. *Aniridia*
E. *X-linked Congenital Retinoschisis*
F. *Presenile Cataracts*

VIII. Genetic testing to establish or confirm the diagnosis of all other eye disorders not specifically discussed within this or another medical policy will be evaluated by the criteria outlined in *General Approach to Genetic Testing and Molecular Testing* (see policy for coverage criteria).

*Clinical features for a specific disorder may be outlined in resources such as GeneReviews, OMIM, National Library of Medicine, Genetics Home Reference, or other scholarly source.

**NOTE:** Refer to *Appendix A* to see the policy statement changes (if any) from the previous version.

---

**Policy Guidelines**

**NOTES AND DEFINITIONS**

1. **Close relatives** include first, second, and third degree blood relatives on the same side of the family:
   a. **First-degree relatives** are parents, siblings, and children
b. **Second-degree relatives** are grandparents, aunts, uncles, nieces, nephews, grandchildren, and half siblings

c. **Third-degree relatives** are great grandparents, great aunts, great uncles, great grandchildren, and first cousins

2. **Age-related Macular Degeneration (AMD)** is the leading cause of blindness and irreversible vision loss among older adults (greater than age 65 years).

3. **Retinal dystrophies (RDs)** are degenerative diseases of the retina which have marked clinical and genetic heterogeneity. Vision impairment may vary from poor peripheral or night vision to complete blindness, and severity usually increases with age.

4. **RPE65 (retinal pigment epithelium-specific protein 65-kD) gene** encodes the RPE54 protein, which is an all translate-retinal isomerase, a key enzyme expressed in the retinal pigment epithelium (RPE) that is responsible for regeneration of 11-cis-retinal in the visual cycle.

5. **Gene Therapies** are treatments that change the expression of genes to treat disease, e.g., by replacing or inactivating a gene that is not functioning properly or by introducing a new gene. Genes may be introduced into human cells through a vector, usually a virus.

**CLINICAL CONSIDERATIONS**

The purpose of genetic testing of asymptomatic individuals with risk of developing age-related macular degeneration is to identify single nucleotide variants for primary prevention or earlier detection of disease for more timely intervention to affect course of disease progression. Patients may be referred from primary care to an ophthalmologist or medical geneticist for investigation and management of age-related macular degeneration. In all cases, the patient should receive counseling from a physician with expertise in inherited disease or a genetic counselor. Whenever clinical findings suggest the presence of an inherited eye disease, the treating ophthalmologist should either discuss the potential value of genetic testing with their patient and order the appropriate tests (if any) or should offer a referral to another physician or counselor with expertise in the selection and interpretation of genetic tests. Treating physicians should also ensure that their patients receive a written copy of their genetic test results.

Genetic testing is required to detect the presence of pathogenic or likely pathogenic variants in the RPE65 gene in individuals with documented vision loss. By definition, pathogenic or likely pathogenic variant(s) must be present in both copies of the RPE65 gene to establish a diagnosis of biallelic RPE65-mediated inherited retinal dystrophy. Next-generation sequencing and Sanger sequencing typically cannot resolve the phase (e.g., trans vs. cis configuration) when two RPE65 pathogenic or likely pathogenic variants are detected. In this scenario, additional documentation of the trans configuration is required to establish a diagnosis of biallelic RPE65-mediated inherited retinal dystrophy.

**Description**

In the past 15 years, genetics experts have identified approximately 500 genes that contribute to inherited eye diseases. Approximately 4,000 diseases affect humans, and nearly one-third of these diseases may affect the eyes. Because many genes involved in ophthalmologic disorders are now identified, scientists have developed a better understanding of how these genes influence vision and eye health.

Age-related macular degeneration (AMD) is an eye condition that causes damage to the central portion of the retina (the macula), affecting the ability to see objects straight ahead. It is a complex disease and is the leading cause of blindness and irreversible vision loss among adults over the age of 65 years. The etiology of AMD is multifactorial and includes both genetic and environmental (e.g., age, smoking) factors. Genetic testing has been proposed to predict the risk of developing advanced AMD in asymptomatic individuals, however, the clinical utility of genetic testing for age-related...
macular degeneration is limited. No studies have shown improvements in patients identified as being high-risk based on genetic testing, and evidence is insufficient to determine the effects of genetic testing on health outcomes. For individuals who have age-related macular degeneration, the clinical utility of genetic testing is limited and has not shown to be superior to clinical evaluation.

The molecular genetic basis for glaucoma has not been clearly elucidated, however a small subset of genes have been identified in very rare forms of congenital glaucoma.

Inherited retinal dystrophy can be caused by biallelic variants in the RPE65 gene and other genes and can result in difficulty seeing in dim light and progressive loss of vision. Historically considered untreatable, gene therapy has been proposed as a treatment to improve visual function. Individuals who have vision loss due to biallelic RPE65 variant associated retinal dystrophy are eligible to receive gene therapy. Because this is a rare condition, there are challenges with generating evidence demonstrating that the technology results in a meaningful improvement in net health outcomes.

Related Policies

This policy document provides coverage criteria for Genetic Testing for Eye Disorders. Please refer to:

- **Genetic Testing: Hereditary Cancer Susceptibility** for coverage criteria related to genetic testing for retinoblastoma. (To be published)
- **Genetic Testing: Hearing Loss** for coverage criteria related to genetic testing for disorders that include hearing loss, such as Usher syndrome. (To be published)
- **Genetic Testing: Multisystem Inherited Disorders, Intellectual Disability, and Developmental Delay** for coverage criteria related to oculocutaneous albinism and other multisystem inherited disorders. (To be published)
- **Genetic Testing: General Approach to Genetic Testing and Molecular Testing** for coverage criteria related to genetic testing for eye disorders that are not specifically discussed in this or another non-general policy.

Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

Rationale

**Background and Rationale**

**Known Familial Variant Analysis for Eye Disorders**

*Genetic Support Foundation*

The Genetic Support Foundation’s Genetics 101 information on genetic testing says the following about testing for familial pathogenic variants:

Genetic testing for someone who may be at risk for an inherited disease is always easier if we know the specific genetic cause. Oftentimes, the best way to find the genetic cause is to start by testing someone in the family who is known or strongly suspected to have the disease. If their testing is positive, then we can say that we have found the familial pathogenic (harmful)
variant. We can use this as a marker to test other members of the family to see who is also at risk.

**Macular Degeneration**

*American Society of Retina Specialists*

American Society of Retina Specialists (2017) published special correspondence on the use of genetic testing in the management of patients with age-related macular degeneration, which made the following conclusions:

1. Age-related macular degeneration (AMD) genetic testing may provide information on the progression rates from intermediate to advanced AMD. However, before ordering this testing, retina specialists should be aware of the following:
   a. Testing should be performed only at Clinical Laboratory Improvement Amendments–certified laboratories with expertise in genetic sequencing. Because of the high variability in the results, direct-to-consumer (DTC) AMD genetic testing that does not meet this standard is not recommended.
   b. Interpretation of the results of AMD genetic testing is complex.
   c. At present, there is no clinical evidence that altering the management of genetically higher risk progression patients, for example, with more frequent office visits and/or improved lifestyle changes, results in better visual outcomes for these patients compared with individuals of lower genetic susceptibility. As such, prospective studies are needed before patient care is modified.

2. Age-related macular degeneration genetic testing at present in patients with neovascular AMD does not provide clinically relevant information regarding response to anti-vascular endothelial growth factor (VEGF) treatment and is not recommended for this purpose.

3. Although genetic testing to determine the optimal nutritional supplementation may in the future prove useful, at present there is insufficient data to support the use of genetic testing in patients with AMD prior to recommendation of current Age-Related Eye Disease Study (AREDS) nutritional supplement use.

**RPE65 Sequencing and/or Deletion/Duplication Analysis or Multigene Panel Analysis**

*US Food and Drug Administration (FDA)*

The FDA issued an approval letter on December 18, 2017 for Luxturna stating, “Under this license, you are authorized to manufacture the product voretigene neparvovec-rzyl, which is indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy.”

**National Institute for Health and Care Excellence**

The National Institute for Health and Care Excellence published guidance for the use of voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations, which stated the following:

1.1 Voretigene neparvovec is recommended, within its marketing authorisation, as an option for treating RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherited retinal dystrophy from confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells. It is recommended only if the company provides voretigene neparvovec according to the commercial arrangement.

The committee noted that, “RPE65-mediated inherited retinal dystrophies are rare and serious. They involve progressive loss of vision. This ultimately leads to near-total blindness, and severely affects the quality of life of people with the condition, and their families and carers. Current treatment is supportive care. Clinical trial evidence shows that, in the short term, voretigene neparvovec improves vision and prevents the condition from getting worse.”

**American Academy of Ophthalmology (AAO)**

The American Academy of Ophthalmology (AAO) Task Force on Genetic Testing published recommendations for genetic testing of inherited eye diseases (2014). In it, they state “there are some
situations in which limited parallel testing is the most effective strategy. When a clinical disease is caused by multiple different genes (e.g., nonsyndromic retinitis pigmentosa, Usher syndrome, Leber congenital amaurosis, and Bardet Biedl syndrome), it often is best to order a single test that has been designed specifically to evaluate efficiently all of the genes known to cause the patient’s clinical findings”. They also recommend that one should “offer genetic testing to patients with clinical findings suggestive of a Mendelian disorder whose causative gene(s) have been identified.”

Glaucoma

American Academy of Ophthalmology (AAO)
The American Academy of Ophthalmology (AAO) Task Force on Genetic Testing published recommendations for genetic testing of inherited eye diseases (2014) which stated, in part: “Avoid routine genetic testing for genetically complex disorders like age-related macular degeneration and late-onset primary open-angle glaucoma until specific treatment or surveillance strategies have been shown in 1 or more published prospective clinical trials to be of benefit to individuals with specific disease-associated genotypes. In the meantime, confine the genotyping of such patients to research studies.”

OTHER COVERED EYE DISORDERS

General Testing Guidelines for Genetic Eye Disorders

American Academy of Ophthalmology (AAO)
The American Academy of Ophthalmology (AAO) Task Force on Genetic Testing published the following recommendations for genetic testing of inherited eye diseases (2014):

1. Offer genetic testing to patients with clinical findings suggestive of a Mendelian disorder whose causative gene(s) have been identified. If unfamiliar with such testing, refer the patient to a physician or counselor who is. In all cases, ensure that the patient receives counseling from a physician with expertise in inherited disease or a certified genetic counselor.

2. Use Clinical Laboratories Improvement Amendments– approved laboratories for all clinical testing. When possible, use laboratories that include in their reports estimates of the pathogenicity of observed genetic variants that are based on a review of the medical literature and databases of disease-causing and non–disease-causing variants.

3. Provide a copy of each genetic test report to the patient so that she or he will be able independently to seek mechanism-specific information, such as the availability of gene-specific clinical trials, should the patient wish to do so.

4. Avoid direct-to-consumer genetic testing and discourage patients from obtaining such tests themselves. Encourage the involvement of a trained physician, genetic counselor, or both for all genetic tests so that appropriate interpretation and counseling can be provided.

5. Avoid unnecessary parallel testing— order the most specific test(s) available given the patient’s clinical findings. Restrict massively parallel strategies like whole-exome sequencing and whole-genome sequencing to research studies conducted at tertiary care facilities.

6. Avoid routine genetic testing for genetically complex disorders like age-related macular degeneration and late-onset primary open-angle glaucoma until specific treatment or surveillance strategies have been shown in 1 or more published prospective clinical trials to be of benefit to individuals with specific disease-associated genotypes. In the meantime, confine the genotyping of such patients to research studies.

7. Avoid testing asymptomatic minors for untreatable disorders except in extraordinary circumstances. For the few cases in which such testing is believed to be warranted, the following steps should be taken before the test is performed: (1) the parents and child should undergo formal genetic counseling, (2) the certified counselor or physician performing the counseling should state his or her opinion in writing that the test is in the family’s best interest, and (3) all parents with custodial responsibility for the child should agree in writing with the decision to perform the test.
References

8. Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD). World Wide Web URL: https://omim.org/

Documentation for Clinical Review

Please provide the following documentation:

- Name of the test being requested or the Concert Genetics GTU identifier.
  The Concert Genetics GTU can be found at https://app.concertgenetics.com
- CPT codes to be billed for the particular genetic test (GTU required for unlisted codes)
- History and physical and/or consultation notes including:
  - Clinical findings:
    - Signs/symptoms leading to a suspicion of genetic condition
    - Family history if applicable
  - Prior evaluation/treatment:
    - Previous test results (i.e., imagining, lab work, etc.) related to reason for genetic testing
    - Family member’s genetic test result, if applicable
  - Rationale
    - Reason for performing test
    - How test result will impact clinical decision making

Post Service (in addition to the above, please include the following):
- Results/reports of tests performed

Coding

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy.
The following codes are included below for informational purposes. Inclusion or exclusion of a code(s) does not constitute or imply member coverage or provider reimbursement policy. Policy Statements are intended to provide member coverage information and may include the use of some codes for clarity. The Policy Guidelines section may also provide additional information for how to interpret the Policy Statements and to provide coding guidance in some cases.

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT*</td>
<td>0205U</td>
<td>Ophthalmology (age-related macular degeneration), analysis of 3 gene variants (2 CFH gene, 1 ARMS2 gene), using PCR and MALDI-TOF, buccal swab, reported as positive or negative for neovascular age-related macular-degeneration risk associated with zinc supplements</td>
</tr>
<tr>
<td></td>
<td>81400</td>
<td>MOLECULAR PATHOLOGY PROCEDURE LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>81401</td>
<td>MOLECULAR PATHOLOGY PROCEDURE LEVEL 2</td>
</tr>
<tr>
<td></td>
<td>81402</td>
<td>MOLECULAR PATHOLOGY PROCEDURE LEVEL 3</td>
</tr>
<tr>
<td></td>
<td>81403</td>
<td>MOLECULAR PATHOLOGY PROCEDURE LEVEL 4</td>
</tr>
<tr>
<td></td>
<td>81404</td>
<td>MOLECULAR PATHOLOGY PROCEDURE LEVEL 5</td>
</tr>
<tr>
<td></td>
<td>81405</td>
<td>MOLECULAR PATHOLOGY PROCEDURE LEVEL 6</td>
</tr>
<tr>
<td></td>
<td>81406</td>
<td>MOLECULAR PATHOLOGY PROCEDURE LEVEL 7</td>
</tr>
<tr>
<td></td>
<td>81407</td>
<td>MOLECULAR PATHOLOGY PROCEDURE LEVEL 8</td>
</tr>
<tr>
<td></td>
<td>81408</td>
<td>MOLECULAR PATHOLOGY PROCEDURE LEVEL 9</td>
</tr>
<tr>
<td></td>
<td>81479</td>
<td>Unlisted molecular pathology procedure</td>
</tr>
<tr>
<td></td>
<td>81599</td>
<td>Unlisted multianalyte assay with algorithmic analysis</td>
</tr>
</tbody>
</table>

Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/01/2023</td>
<td>New policy.</td>
</tr>
</tbody>
</table>

Definitions of Decision Determinations

**Medically Necessary:** Services that are Medically Necessary include only those which have been established as safe and effective, are furnished under generally accepted professional standards to treat illness, injury or medical condition, and which, as determined by Blue Shield, are: (a) consistent with Blue Shield medical policy; (b) consistent with the symptoms or diagnosis; (c) not furnished primarily for the convenience of the patient, the attending Physician or other provider; (d) furnished at the most appropriate level which can be provided safely and effectively to the patient; and (e) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the Member’s illness, injury, or disease.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will
be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

**Prior Authorization Requirements and Feedback (as applicable to your plan)**

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department at (800) 541-6652, or the Transplant Case Management Department at (800) 637-2066 ext. 3507708 or visit the provider portal at www.blueshieldca.com/provider.

We are interested in receiving feedback relative to developing, adopting, and reviewing criteria for medical policy. Any licensed practitioner who is contracted with Blue Shield of California or Blue Shield of California Promise Health Plan is welcome to provide comments, suggestions, or concerns. Our internal policy committees will receive and take your comments into consideration.

For utilization and medical policy feedback, please send comments to: MedPolicy@blueshieldca.com

*Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.*
# Appendix A

<table>
<thead>
<tr>
<th>POLICY STATEMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BEFORE</strong></td>
</tr>
<tr>
<td>Red font: Verbiage removed</td>
</tr>
<tr>
<td><strong>Genetic Testing for Macular Degeneration 2.04.103</strong></td>
</tr>
<tr>
<td><strong>Policy Statement:</strong></td>
</tr>
<tr>
<td><strong>KNOWN FAMILIAL VARIANT ANALYSIS FOR EYE DISORDERS</strong></td>
</tr>
</tbody>
</table>
| I. Targeted mutation analysis for a known familial variant (81403) for an eye disorder may be considered medically necessary when:  
A. The member has a close relative with a known pathogenic or likely pathogenic variant causing the condition. | I. Targeted mutation analysis for a known familial variant (81403) for an eye disorder may be considered medically necessary when:  
A. The member has a close relative with a known pathogenic or likely pathogenic variant causing the condition.  
II. Targeted mutation analysis for a known familial variant (81403) for an eye disorder is considered investigational for all other indications. |
| **MACULAR DEGENERATION** | **MACULAR DEGENERATION** |
| III. Genetic testing for macular degeneration (81404, 81406, 81408, 81479, 81599, 0205U) is considered investigational. | III. Genetic testing for macular degeneration (81404, 81406, 81408, 81479, 81599, 0205U) is considered investigational. |
| **RPE65-ASSOCIATED RETINAL DYSTROPHY / LEBER CONGENITAL AMAUROSIS** | **RPE65-ASSOCIATED RETINAL DYSTROPHY / LEBER CONGENITAL AMAUROSIS** |
| **RPE65 Sequencing and/or Deletion/Duplication Analysis or Multigene Panel Analysis** | **RPE65 Sequencing and/or Deletion/Duplication Analysis or Multigene Panel Analysis** |
| IV. Genetic testing for RPE65-associated retinal dystrophy/Leber congenital amaurosis via RPE65 sequencing and/or deletion/duplication analysis (81406, 81479) or a multigene panel (81404, 81406, 81408, 81479) that includes RPE65 may be considered medically necessary when BOTH of the following criteria are met:  
A. The member has a diagnosis of a retinal dystrophy or Leber Congenital Amaurosis  
B. The member is being considered for treatment with voretigene neparvovec (Luxturna®). | IV. Genetic testing for RPE65-associated retinal dystrophy/Leber congenital amaurosis via RPE65 sequencing and/or deletion/duplication analysis (81406, 81479) or a multigene panel (81404, 81406, 81408, 81479) that includes RPE65 may be considered medically necessary when BOTH of the following criteria are met:  
A. The member has a diagnosis of a retinal dystrophy or Leber Congenital Amaurosis  
B. The member is being considered for treatment with voretigene neparvovec (Luxturna®).  
V. Genetic testing for RPE65-associated retinal dystrophy/Leber congenital amaurosis via RPE65 sequencing and/or deletion/duplication analysis (81406, 81479) or a multigene panel (81404, 81406, 81408, 81479) that includes RPE65 may be considered medically necessary when BOTH of the following criteria are met:  
A. The member has a diagnosis of a retinal dystrophy or Leber Congenital Amaurosis  
B. The member is being considered for treatment with voretigene neparvovec (Luxturna®). |
### POLICY STATEMENT

<table>
<thead>
<tr>
<th>BEFORE</th>
<th>AFTER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Red font: Verbiage removed</strong></td>
<td><strong>Blue font: Verbiage Changes/Additions</strong></td>
</tr>
</tbody>
</table>

#### GLAUCOMA

- Genetic testing for glaucoma (81404, 81406, 81407, 81408, 81479) is considered **investigational** for all other indications.

#### OTHER COVERED EYE DISORDERS

The following is a list of conditions that have a known genetic association. Due to their relative rareness, it may be appropriate to approve claims for these tests to establish or confirm a diagnosis.

- Genetic testing to establish or confirm one of the following eye disorders to guide management may be considered **medically necessary** when the member demonstrates clinical features* consistent with the disorder (the list is not meant to be comprehensive, see VIII below):
  - G. Duane Syndrome
  - H. Familial Exudative Vitreoretinopathy
  - I. Retinitis Pigmentosa
  - J. Aniridia
  - K. X-linked Congenital Retinoschisis
  - L. Presenile Cataracts

- Genetic testing to establish or confirm the diagnosis of all other eye disorders not specifically discussed within this or another medical policy will be evaluated by the criteria outlined in *General Approach to Genetic Testing and Molecular Testing* (see policy for coverage criteria).

*Clinical features for a specific disorder may be outlined in resources such as GeneReviews, OMIM, National Library of Medicine, Genetics Home Reference, or other scholarly source.